Table 2. SABA contribution to sold pMDI and DPI doses in selected European countries§ in 2021.
| Number of sold doses (million)* | Carbon footprint (kt CO2e) | |
|---|---|---|
| Total inhaler (pMDI+DPI) doses sold, 2021† | 41 559 | 3995 |
| SABA (pMDI+DPI)‡ | 13 887 | 1642 |
| SABA (pMDI) | 13 067 | 1633 |
| SABA (DPI) | 820 | 8 |
*
Numbers reflect rounding.
†
Soft mist inhaler and nebuliser sales are not included in the analysis.
‡
The SABA molecules considered included salbutamol, fenoterol and terbutaline.
§
Selected European countries include Denmark, Finland, France, Germany, Italy, Norway, Spain, Sweden and the UK. SABA sales data from Poland were not available. Based on IQVIA MIDAS Quarterly sales data for the year 2021, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.
CO2e, carbon dioxide equivalents; DPI, dry powder inhaler; kt, metric kilotons; pMDI, pressurised metered dose inhaler; SABA, short-acting beta-2 agonist.